Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Share-based Compensation (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Share-based Compensation for 16 consecutive years, with $713000.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 457.03% to $713000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 180.0% year-over-year, with the annual reading at $1.5 million for FY2025, 180.0% up from the prior year.
  • Share-based Compensation for Q4 2025 was $713000.0 at Plus Therapeutics, up from $527000.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $713000.0 in Q4 2025, with the low at $107000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $198352.9, with a median of $146000.0 recorded in 2024.
  • The sharpest move saw Share-based Compensation soared 791.67% in 2021, then decreased 22.22% in 2023.
  • Over 5 years, Share-based Compensation stood at $107000.0 in 2021, then rose by 21.5% to $130000.0 in 2022, then rose by 8.46% to $141000.0 in 2023, then fell by 9.22% to $128000.0 in 2024, then skyrocketed by 457.03% to $713000.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $713000.0, $527000.0, and $152000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.